Prognostic significance of autoimmunity during treatment of melanoma with interferon

[1]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon. , 2011, Seminars in immunopathology.

[2]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[3]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[4]  V. Sondak,et al.  Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma , 2010, Cancer Chemotherapy and Pharmacology.

[5]  David C. Smith,et al.  Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. , 2010 .

[6]  A. Eggermont,et al.  Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Ascierto,et al.  Melanoma: A model for testing new agents in combination therapies , 2010, Journal of Translational Medicine.

[8]  A. Hauschild,et al.  Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. , 2010, European journal of cancer.

[9]  Shimon Sakaguchi,et al.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity , 2010, Nature Immunology.

[10]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Almenar,et al.  [Problems in defining melanoma regression and prognostic implication]. , 2009, Actas dermo-sifiliograficas.

[12]  K. Drzewiecki,et al.  Spontaneous regression of metastases from melanoma: review of the literature , 2009, Melanoma research.

[13]  S. Aamdal,et al.  Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.

[14]  J. Kirkwood,et al.  Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? , 2009, Nature Clinical Practice Oncology.

[15]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[16]  J. Kirkwood,et al.  Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696 , 2007 .

[17]  D. Jukic,et al.  Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b , 2007, Clinical Cancer Research.

[18]  K. Busam,et al.  Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy , 2007, Annals of Surgical Oncology.

[19]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Jukic,et al.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Martin A Weinstock,et al.  Cutaneous melanoma: public health approach to early detection , 2006, Dermatologic therapy.

[22]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[23]  A. Ribas,et al.  Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma , 2005 .

[24]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[25]  G. Dranoff.  CTLA-4 blockade: unveiling immune regulation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Sakaguchi,et al.  Regulatory T Cells in Immunologic Self-Tolerance and Autoimmune Disease , 2005, International reviews of immunology.

[28]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[29]  W. Greer,et al.  Partial Regression of Primary Cutaneous Melanoma: Is There an Association with Sub-Clinical Sentinel Lymph Node Metastasis? , 2003, The American Journal of dermatopathology.

[30]  H. Ochs,et al.  Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis , 2003, Current opinion in rheumatology.

[31]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Hori,et al.  Control of autoimmunity by naturally arising regulatory CD4+ T cells. , 2003, Advances in immunology.

[33]  E. Herrmann,et al.  Pharmacokinetics of Peginterferons , 2003, Seminars in liver disease.

[34]  J. Kirkwood,et al.  Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[36]  F. Powrie,et al.  Control of intestinal inflammation by regulatory T cells. , 2001, Microbes and infection.

[37]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Steinberg,et al.  Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Manns,et al.  Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C , 2001, Gut.

[41]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Brabant,et al.  Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Caraceni,et al.  Neurotoxicity of interferon‐α in melanoma therapy , 1998 .

[44]  K. Kälkner,et al.  Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. , 1998, QJM : monthly journal of the Association of Physicians.

[45]  B. Williams,et al.  Signal transduction in the interferon system. , 1998, Seminars in oncology.

[46]  A. Caraceni,et al.  Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. , 1998, Cancer.

[47]  P. Yeo,et al.  Interferon-α Induced Thyroid Dysfunction: Three Clinical Presentations and a Review of the Literature , 1997 .

[48]  A. Horsch,et al.  Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy , 1997, Hepatology.

[49]  P. Yeo,et al.  Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. , 1997, Thyroid : official journal of the American Thyroid Association.

[50]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  I. Jackson,et al.  The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. , 1996, Human molecular genetics.

[52]  T. Okanoue,et al.  Side effects of high-dose interferon therapy for chronic hepatitis C. , 1996, Journal of hepatology.

[53]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[54]  G. Martinelli,et al.  Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. , 1996, Haematologica.

[55]  S. Steinberg,et al.  Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[56]  G. Lutfalla,et al.  α and α Interferons and Their Receptor and Their Friends and Relations , 1995 .

[57]  L. Cavanna,et al.  Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. , 1995, Acta haematologica.

[58]  G. Lutfalla,et al.  Alpha and beta interferons and their receptor and their friends and relations. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[59]  L. Naldi,et al.  Antiphospholipid syndrome associated with immunotherapy for patients with melanoma , 2006 .

[60]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[61]  J. Becker,et al.  Antiphospholipid syndrome associated with immunotherapy for patients with melanoma , 1994, Cancer.

[62]  N. Weijl,et al.  Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  K. Schallreuter,et al.  Vitiligo and cutaneous melanoma. A case study. , 1991, Dermatologica.

[64]  P. Carlini,et al.  Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. , 1990, European journal of cancer.

[65]  M. Atkins,et al.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, The New England journal of medicine.

[66]  J. Kirkwood,et al.  A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  A. Kopf,et al.  Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.

[68]  D. Ahmann,et al.  Phase II study of recombinant leukocyte a interferon (rIFN‐αA) in disseminated malignant melanoma , 1984, Cancer.

[69]  D. Ahmann,et al.  Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. , 1984, Cancer.

[70]  J. Kirkwood,et al.  Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.

[71]  A. Kopf,et al.  Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. , 1980, Cancer research.

[72]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[73]  D.,et al.  Regression Models and Life-Tables , 2022 .